Adamis Pharmaceuticals Announces Investor Update Conference Call

Adamis Pharmaceuticals Announces Investor Update Conference Call 
SAN DIEGO, CA -- (Marketwired) -- 08/09/13 --  Adamis Pharmaceuticals
Corp. (OTCQB: ADMP) ("the Company"), a biopharmaceutical company
engaged in the development and commercialization of specialty
pharmaceutical and biotechnology products in the therapeutic areas of
respiratory disease, allergy, oncology and immunology, will host an
investor conference call on Tuesday, August 13, 2013 at 4:15pm ET to
provide a business update concerning the Company's recent corporate
developments. The Company's President and CEO, Dr. Dennis Carlo, will
host the call. 
Date: Tuesday, August 13, 2013 
Time: 4:15pm ET (1:15pm PT) 
US Dial-in (Toll-free): 1-855-327-6837 
TOLL/International Dial-in: 1-778-327-3988 
Reference: Adamis Pharmaceuticals Investor Update Conference Call 
A playback of the call will be available from 7:15pm ET on August 13,
2013 until 11:59 pm ET on August 20, 2013. To listen to the replay,
call toll free 1-877-870-5176 within the United States or
1-858-384-5517 when calling internationally (toll). Please use the
replay PIN number 105752. 
About Adamis Pharmaceuticals Corporation 
Adamis Pharmaceuticals Corporation is a biopharmaceutical company
engaged in the development and commercialization of specialty
pharmaceutical and biotechnology products in the therapeutic areas of
respiratory disease, allergy, oncology and immunology. Products in
its specialty pharmaceutical pipeline include the Epinephrine
Injection PFS syringe for use in the emergency treatment of
anaphylaxis, APC-1000 and APC-5000 for the treatment of asthma and
chronic obstructive pulmonary disease, and APC-3000, a HFA inhaled
nasal steroid product for the treatment of allergic rhinitis. Product
candidates currently in development within its biotechnology pipeline
include TeloB-VAX, a novel cell-based therapeutic cancer vaccine, and
three drug product candidates, APC-100, APC-200, and APC-300, for the
treatment of prostate cancer and inflammation. 
Forward Looking Statements 
This press release may contain forward-looking statements that relate
to future events or our future results of operations or future
financial performance, including, but not limited to the following
statements: the ability to fund future product development and
business operations; future revenues expected from any of the
company's product candidates, assuming that they are developed and
approved for marketing by the FDA and other regulatory authorities;
our ability to complete any future acquisitions of products, product
candidates or technologies; and the intellectual property protection
that may be afforded by any patents or patent applications relating
to the company's technology. Certain of these risks, uncertainties,
and other factors are described in greater detail in Adamis' filings
from time to time with the SEC, which Adamis strongly urges you to
read and consider, all of which are available free of charge on the
SEC's web site at http://www.sec.gov. Except as required by law,
Adamis expressly disclaims any obligation to update any
forward-looking statements. 
Related Links: http://adamispharmaceuticals.com/ 
For Additional Information 
Mark Flather
Director, Investor Relations & Corporate Communications
Adamis Pharmaceuticals Corp.
Tel: 858- 412-7951
Email: mflather@adamispharma.com 
 
 
Press spacebar to pause and continue. Press esc to stop.